Search results for "breast neoplasms"

showing 10 items of 804 documents

Correlation of serum and salivary CA15-3 levels in patients with breast cancer

2008

Objectives: The aim of this study was to assess the relationship between serum and saliva levels of cancer antigen (CA) 15-3 and to compare them between women with and without breast cancer. Study design: A case-control study was carried out on 61 women aged 28-69 years, including women with and without breast cancer (26 as part of the case study and 35 as part of the control group) conducted at the Emam Khomeini Hospital, Tehran University of Medical Sciences. CA15-3 levels were assayed in serum and unstimulated whole saliva by EIA. Unpaired t-test, one-way ANOVA and Pearson correlation were used as statistical analysis. Results: The salivary and serological levels of CA15-3 in the cancer …

CA15-3Adultmedicine.medical_specialtySalivaBreast NeoplasmsGastroenterologySerologyBreast cancerInternal medicinemedicineHumansStage (cooking)SalivaGeneral DentistryAgedbusiness.industryMucin-1Case-control studyCancerMiddle Agedmedicine.disease:CIENCIAS MÉDICAS [UNESCO]EndocrinologyOtorhinolaryngologyCase-Control StudiesUNESCO::CIENCIAS MÉDICASSurgeryFemaleAnalysis of variancebusiness
researchProduct

Difference in Ki67 and thymidylate synthase expression in primary tumour compared with metastatic nodes in breast cancer patients.

2005

Breast cancer is a heterogeneous disease, so therapeutic predictive biological markers need to be identified. To date an accurate evaluation of predictive markers is mainly done at the primary site; however, the main goal of adjuvant therapy for breast cancer is the control of micrometastases. The aim of this study is to assess as therapeutic and/or prognostic marker, the proliferation status of primary tumors and involved nodes as measured by Ki67 and thymidylate synthase (TS) expression, in 30 breast cancer node positive patients. TS is the main target of 5-fluorouracil (5-FU) activity, and its overexpression is one of the mechanisms of 5-FU drug resistance; however, in some studies its a…

CA15-3Antimetabolites AntineoplasticProliferation indexBreast NeoplasmsDiseaseDrug resistanceBiologySettore MED/08 - Anatomia PatologicaBiochemistryThymidylate synthaseGene Expression Regulation EnzymologicBreast cancerbreast cancerAntigens NeoplasmGeneticsmedicineAdjuvant therapyHumansNeoplasm MetastasisCell ProliferationGeneral MedicineThymidylate SynthaseCell cyclemedicine.diseasePrognosisGene Expression Regulation NeoplasticKi-67 AntigenmetastaseLymphatic MetastasisImmunologyCancer researchbiology.proteinMolecular MedicineFemaleFluorouracilKi67Nucleosides, nucleotidesnucleic acids
researchProduct

Coordinates in the Universe of Node-Negative Breast Cancer Revisited

2009

Abstract We present a global picture of the natural history of node-negative breast cancer in which two of three important biological processes have outstanding prognostic consequences. We propose that the transition from slow to fast proliferation of the tumor leads to the most dramatic aggravation of prognosis. Second, immune cell infiltration is of major importance to prevent disease progression in fast-proliferating breast carcinomas, regardless of estrogen receptor status. In the absence of endocrine treatment, steroid hormone receptor expression as a third axis is of limited prognostic importance. Dissecting tumors according to these three major biological axes will allow further unde…

CA15-3Cancer ResearchPathologymedicine.medical_specialtySteroid hormone receptorbusiness.industryCancerBreast Neoplasmsmedicine.diseaseBreast cancerOncologyTumor progressionLymphatic MetastasismedicineCancer researchHumansEndocrine systemFemaleLymph NodesBreast diseasebusinessEstrogen Receptor StatusCancer Research
researchProduct

Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications.

2007

Abstract The clinical significance of serum cathepsin K and cystatin C was assessed in patients with breast cancer (BCa) or prostate cancer (PCa) with confined disease (M0) or bone metastasis (BM). Cathepsin K and cystatin C circulating levels were determined by ELISAs in 63 cancer patients, in 35 patients with nonmalignant diseases and in 42 healthy blood donors (control group). In BCa patients, cathepsin K serum levels were significantly lower than in sex matched control group (HS; p  = 0.0008) or in patients with primary osteoporosis (OP; p  = 0.0009). On the contrary, cystatin C levels were significantly higher in BCa patients than in HS ( p  = 0.0001) or OP ( p  = 0.017). In PCa patien…

CA15-3Malemedicine.medical_specialtyCathepsin KProstatic HyperplasiaBone NeoplasmsBreast NeoplasmsEnzyme-Linked Immunosorbent Assayurologic and male genital diseasesZoledronic AcidProstate cancerInternal medicinemedicineCathepsin KBiomarkers TumorHumansCystatin CAgedPharmacologyAged 80 and overbiologyBone Density Conservation AgentsDiphosphonatesbusiness.industryBone cancerImidazolesCancerBone metastasisProstatic NeoplasmsGeneral MedicineMiddle Agedmedicine.diseaseCathepsinsCystatinsBone metastasis; cathepsin K; Cystatin CEndocrinologyZoledronic acidCystatin CROC CurveBone metastasiCase-Control Studiesbiology.proteinDisease ProgressionOsteoporosisFemaleDrug Monitoringbusinessmedicine.drugBiomedicinepharmacotherapy = Biomedecinepharmacotherapie
researchProduct

Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes

2012

BACKGROUND The aim of this study is to evaluate the impact of the different breast cancer subtypes on the tumor (18)F-FDG uptake at baseline and on its changes after the first course of neoadjuvant chemotherapy (NAC). PATIENTS AND METHODS One hundred and fifteen women with newly diagnosed, large or locally advanced breast cancer undergoing NAC were included. Estrogen receptor (ER), progesterone receptor (PR) and HER2 status were used to define three major tumor subtypes: triple negative (TN) (ER-/PR-/HER2-), luminal (ER+ and/or PR+; HER2-) and HER2 positive (HER2+). Using Fluorine-18 fluorodeoxyglucose positron emission tomography, the tumoral standard uptake value (SUV) maximal index was m…

CA15-3Oncologymedicine.medical_specialtymedicine.medical_treatmentEstrogen receptorStandardized uptake valueAntineoplastic AgentsBreast Neoplasms[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicineMultimodal Imaging030218 nuclear medicine & medical imaging[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciences0302 clinical medicineBreast cancerFluorodeoxyglucose F18Internal medicineProgesterone receptormedicineHumansskin and connective tissue diseasesPathologicalComputingMilieux_MISCELLANEOUSChemotherapybusiness.industryHematologyMetabolismmedicine.disease3. Good healthOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisPositron-Emission TomographyFemalebusinessTomography X-Ray Computed
researchProduct

Plasma membrane and lysosomal localization of CB1 cannabinoid receptor are dependent on lipid rafts and regulated by anandamide in human breast cance…

2005

AbstractIn this report we show, by confocal analysis of indirect immunofluorescence, that the type-1 cannabinoid receptor (CB1R), which belongs to the family of G-protein-coupled receptors, is expressed on the plasma membrane in human breast cancer MDA-MB-231 cells. However, a substantial proportion of the receptor is present in lysosomes. We found that CB1R is associated with cholesterol- and sphyngolipid-enriched membrane domains (rafts). Cholesterol depletion by methyl-β-cyclodextrin (MCD) treatment strongly reduces the flotation of the protein on the raft-fractions (DRM) of sucrose density gradients suggesting that CB1 raft-association is cholesterol dependent. Interestingly binding of …

CB1 receptorCannabinoid receptorMESH: Membrane MicrodomainsMESH: Receptor Cannabinoid CB1Biochemistrychemistry.chemical_compoundRaftsMESH: Cholesterol0302 clinical medicineReceptor Cannabinoid CB1Structural BiologyReceptorLipid raft0303 health sciencesChemistrybeta-CyclodextrinsAnandamideEndocannabinoid system3. Good healthCell biologyCholesterollipids (amino acids peptides and proteins)AgonistMESH: beta-CyclodextrinsMESH: Cell Line TumorPolyunsaturated Alkamidesmedicine.drug_classBiophysicsBreast NeoplasmsArachidonic Acids03 medical and health sciencesMembrane MicrodomainsCell Line TumorGeneticsmedicineMESH: Arachidonic AcidsHumansMolecular Biology030304 developmental biologyG protein-coupled receptorMESH: HumansMESH: Polyunsaturated AlkamidesCell Membrane[SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry Molecular Biology/Molecular biologyAnandamideCell BiologyCaveolin 1LysosomesIntracellular traffickingMESH: Breast Neoplasms030217 neurology & neurosurgeryMESH: Cell MembraneMESH: LysosomesEndocannabinoids
researchProduct

Reduced numbers of IL-7 receptor (CD127) expressing immune cells and IL-7-signaling defects in peripheral blood from patients with breast cancer

2007

Interleukin-7-receptor-signaling plays a pivotal role in T-cell development and maintenance of T-cell memory. We studied IL-7Ralpha (CD127) expression in PBMCs obtained from patients with breast cancer and examined IL-7 receptor-mediated downstream effects defined by STAT5 phosphorylation (p-STAT5). Reduced numbers of IL-7Ralpha-positive cells were identified in CD4+ T-cells as well as in a CD8+ T-cell subset defined by CD8alpha/alpha homodimer expression in patients with breast cancer. PBMCs obtained from healthy donors (n = 19) and from patients with breast cancer (n = 19) exhibited constitutive p-STAT5 expression in the range of 0-6.4% in CD4+ T-cells and 0-4% in CD8+ T-cells. Stimulatio…

CD4-Positive T-LymphocytesCancer Researchmedicine.medical_specialtyT-Lymphocytesmedicine.medical_treatmentBreast NeoplasmsCD8-Positive T-LymphocytesPeripheral blood mononuclear cellchemistry.chemical_compoundImmune systemBreast cancerInternal medicineSTAT5 Transcription FactormedicineHumansPhosphorylationInterleukin-7 receptorSTAT5Receptors Interleukin-7biologybusiness.industryInterleukin-7Flow Cytometrymedicine.diseaseRecombinant ProteinsCytokineEndocrinologyOncologychemistryIonomycinLeukocytes Mononuclearbiology.proteinCytokinesFemalebusinessCD8Signal TransductionInternational Journal of Cancer
researchProduct

Non-pegylated liposomal doxorubicin plus cyclophosphamide as first-line therapy in elderly women with HER2 negative metastatic breast cancer.

2022

Background. The use of anthracyclines in metastatic breast cancer (MBC) is limited by cumulative dose-dependent cardiotoxicity mostly in elderly women with comorbidities. The aim of this observational retrospective study was to evaluate the efficacy of non-pegylated liposomal doxorubicin (Myocet®) and cyclophosphamide in elderly women as HER2 negative first-line MBC treatment. Methods. 84 elderly women >70 years of age (median age 78 years) with MBC HER2 negative were enrolled. Performance Status in 58 patients was ECOG-0 and in 26 patients was ECOG-1. Results. The drug was well tolerated, with overall response rates were >40%, median overall survival was 16.2 months (95%CI:14.6- 18.8…

Ca 15-3 Cyclophosphamide Elderly woman Metastatic breast cancer Non-pegylated liposomal doxorubicin Quality of lifeTreatment OutcomeDoxorubicinAntineoplastic Combined Chemotherapy ProtocolsHumansBreast NeoplasmsFemaleCyclophosphamideCardiotoxicityAgedPolyethylene GlycolsRetrospective StudiesLa Clinica terapeutica
researchProduct

Interleukin-30 feeds breast cancer stem cells via CXCL10 and IL23 autocrine loops and shapes immune contexture and host outcome

2021

BackgroundBreast cancer (BC) progression to metastatic disease is the leading cause of death in women worldwide. Metastasis is driven by cancer stem cells (CSCs) and signals from their microenvironment. Interleukin (IL) 30 promotes BC progression, and its expression correlates with disease recurrence and mortality. Whether it acts by regulating BCSCs is unknown and could have significant therapeutic implications.MethodsHuman (h) and murine (m) BCSCs were tested for their production of and response to IL30 by using flow cytometry, confocal microscopy, proliferation and sphere-formation assays, and PCR array. Immunocompetent mice were used to investigate the role of BCSC-derived IL30 on tumor…

Cancer Research2434ImmunologyTriple Negative Breast NeoplasmsBiologyInterleukin-23Paracrine signallingMiceCancer stem cellCell Line Tumorbreast neoplasmsImmunology and Allergytumor microenvironmentAnimalsHumans1506Autocrine signallingRC254-282PharmacologyTumor microenvironmentbreast neoplasms cytokines tumor microenvironmentInterleukinsInnate lymphoid cellNeoplasms. Tumors. Oncology. Including cancer and carcinogensFOXP3Basic Tumor ImmunologyDendritic cellcytokinesChemokine CXCL10Autocrine CommunicationOncologyKLF4Cancer researchNeoplastic Stem CellsMolecular MedicineFemaleJournal for Immunotherapy of Cancer
researchProduct

CtIP silencing as a novel mechanism of tamoxifen resistance in breast cancer.

2007

AbstractAcquired resistance to the antiestrogen tamoxifen constitutes a major clinical challenge in breast cancer therapy. However, the mechanisms involved are still poorly understood. Using serial analysis of gene expression, we identified CtIP, a BRCA1- and CtBP-interacting protein, as one of the most significantly down-regulated transcripts in estrogen receptor α–positive (ER+) MCF-7 tamoxifen-resistant breast cancer cells. We further confirmed the association of CtIP down-regulation with tamoxifen resistance in an additional ER+ breast cancer line (T47D), strengthening the relevance of the phenomenon observed. In additional studies, we found CtIP protein expression in a majority of ER+ …

Cancer ResearchAntineoplastic Agents HormonalEstrogen receptorDown-RegulationBreast NeoplasmsDisease-Free SurvivalBreast cancerCell Line TumormedicineGene silencingHumansSerial analysis of gene expressionGene Silencingskin and connective tissue diseasesMolecular BiologyEndodeoxyribonucleasesbusiness.industryCancerNuclear ProteinsAntiestrogenmedicine.diseaseGrowth InhibitorsGene Expression Regulation NeoplasticTamoxifenOncologyDrug Resistance NeoplasmCancer researchFemalebusinessCarrier ProteinsTamoxifenProgressive diseasemedicine.drugMolecular cancer research : MCR
researchProduct